The Conference on Retroviruses and Opportunistic Infections (CROI) remains a venue for important exchanges of information and dissemination of knowledge. New anti-hepatitis C virus (HCV) therapies remain a focus of interest at CROI 2012. Telaprevir and boceprevir, two recently approved, direct-acting anti-HCV drugs, have now been associated with improved virological responses in patients co-infected with HIV and hepatitis C. However, overlapping toxicities and substantial drug-drug interactions will severely limit their clinical utility. Yet another single-pill, once-daily antiretroviral regimen is on the horizon, and the proof of concept for purging HIV from latent CD4+ cells may have been provided at CROI 2012.
ASJC Scopus subject areas
- Pharmacology (medical)